As noted above, mutations in the SWI/SNF chromatin remodeling complex (e.g., in the SMARCB1 gene) create context‐specific vulnerability to EZH2 inhibition, and durable responses were seen in the Tazemetostat phase I trials in epithelioid sarcomas harboring a loss of SMARCB1 (albeit in very limited sample size of 2 out of 3 patients),26 a basket trial was designed to assess Tazemetostat in solid tumor patients harboring loss of INI1/SMARCB1. The gene discussed is SMARCB1; the disease is epithelioid sarcoma.